Stille's Q2 2026 report beat our estimates on sales by ~7%, but showed softer margins than we had pe...
Aiforia issued a profit warning with H1'26 revenues coming in at a mere € 0.
The prostate theranostics market is expanding fast.
Tonies looks set to report a strong Q2 marked by further accelerating growth, carried by particularl...
Dynavox delivered an in-line topline but a clear profitability beat in Q2, with the EBIT margin alre...
Eastnine erbjuder en unik exponering mot Östeuropas strukturella tillväxt genom moderna prime-kontor...
Atria's Q2 adjusted EBIT of EUR 20.7m was 15% above LSEG Data & Analytics consensus and sales were 1...
Redeye updates its estimates and valuation after Lagercrantz’s Q1 2026/2027 report.
* Q2 volumes pre-announced, we forecast sales -13%, EBIT -28% * Comps ease from Q3, both FX and volu...
* Q2 broadly in line across most line items * '26e-'28e adj.
Redeye updates its estimates and valuation following MedCap’s Q2 2026 report, a broad-based beat ver...
* Order intake +5% y-o-y – an early sign of stabilisation? * We keep '26e adj.
* Launches bike-sharing service with ~700 bikes in Helsinki * Unlikely to trigger material consensus...
* -1%/0% adj. EBITDA vs ABGSCe/Infront cons in Q2 * Cons estimates likely unchanged * Trading at 10.
Yesterday, NanoRepro AG published its consolidated preliminary H1'26 revenue while also highlighting...
Yesterday, MHP released Q2 '26 hotel performance figures, posting the highest quarterly revenue in t...
Redeye comments on Dynavox’s Q2 report released earlier this morning.
Atria reported Q2 adjusted EBIT of EUR 20.7m, 15% above LSEG Data & Analytics consensus.
Redeye updates on Hacksaw after Q2-results which were close to our forecasts, albeit with slightly l...
Physitrack's Q2 marked a return to growth — revenue up 8% and ARR of EUR 13.
